CASI Pharmaceuticals (CASI) Fundamental Analysis: Revenue, Earnings & Valuation

5.57 / 10

Netural

The fundamental score stands at 5.6/10, reflecting a balanced but not outstanding profile. Strengths include favorable Asset-MV (-0.4876) and Cash-MV (-0.0698) values, while weaknesses are evident in a very low Net profit / Total operating revenue (-259.5626%) and a negative Gross profit margin (47.3165, but grouped in a way that indicates risk). Inventory and accounts receivable turnover ratios are moderate. Overall, the company maintains liquidity but profitability remains a concern.

Analysis Checks(4/10)

Revenue-MV

Value-0.72

Score0/3

Weight25.85%

1M Return6.93%

Inventory turnover ratio

Value1.81

Score2/3

Weight-2.77%

1M Return-1.04%

Gross profit margin (%)

Value47.32

Score0/3

Weight-14.88%

1M Return-7.03%

Net cash flow from operating activities / Operating revenue (%)

Value-1510.34

Score1/3

Weight1.23%

1M Return0.46%

Accounts receivable turnover ratio

Value1.50

Score0/3

Weight-2.56%

1M Return-0.93%

Quick ratio

Value0.24

Score1/3

Weight0.17%

1M Return0.06%

Fixed assets turnover ratio

Value1.80

Score2/3

Weight0.52%

1M Return0.17%

Asset-MV

Value-0.49

Score3/3

Weight62.72%

1M Return15.52%

Net profit / Total operating revenue (%)

Value-259.56

Score0/3

Weight-3.57%

1M Return-1.34%

Cash-MV

Value-0.07

Score2/3

Weight33.28%

1M Return8.78%

Is CASI undervalued or overvalued?

CASI scores 5.57/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -183.96% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and -35.43% earnings growth, these metrics solidify its Netural investment rating.

CASI(Delisted)

Analysis Checks(4/10)